{"organizations": [], "uuid": "c9fd30827be0fb1a812fadb61764ec461daa3c75", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rxi-says-determined-interim-financ/brief-rxi-says-determined-interim-financial-statements-for-qtrs-ended-march-31-june-30-sept-30-2017-should-no-longer-be-relied-upon-idUSFWN1R811E", "country": "US", "domain_rank": 408, "title": "BRIEF-RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-03-27T04:57:00.000+03:00", "replies_count": 0, "uuid": "c9fd30827be0fb1a812fadb61764ec461daa3c75"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rxi-says-determined-interim-financ/brief-rxi-says-determined-interim-financial-statements-for-qtrs-ended-march-31-june-30-sept-30-2017-should-no-longer-be-relied-upon-idUSFWN1R811E", "ord_in_thread": 0, "title": "BRIEF-RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "rxi", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "rxi pharmaceuticals corp", "sentiment": "neutral"}, {"name": "rxi pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Rxi Pharmaceuticals Corp:\n* RXI - ON MARCH 20, DETERMINED INTERIM FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, JUNE 30, AND SEPT 30, 2017 SHOULD NO LONGER BE RELIED UPON‍​\n* RXI PHARMACEUTICALS - ‍ADJUSTMENT IN RESTATED INTERIM FINANCIAL STATEMENTS FOR PRIOR PERIODS IS A NON-CASH CHARGE​\n* RXI - ‍ADJUSTMENT IN RESTATED STATEMENTS DID NOT AFFECT PREVIOUSLY REPORTED NET LOSS/OPERATING CASH FLOWS, HAD NO IMPACT ON BALANCE SHEET​\n* RXI - CONCLUDED INTERNAL CONTROL DEFICIENCIES SPECIFIC TO ISSUE REPRESENT ‘MATERIAL WEAKNESS’ IN INTERNAL CONTROL OVER FINANCIAL REPORTING​\n* RXI - DETERMINED CO'S DISCLOSURE CONTROLS & PROCEDURES WERE NOT EFFECTIVE FOR PRIOR PERIODS​ Source text: [ bit.ly/2uk8hHF ] Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://bit.ly/2uk8hHF", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T04:57:00.000+03:00", "crawled": "2018-03-27T11:37:56.015+03:00", "highlightTitle": ""}